My ePortfolio Register   

ESMO 2017 /
Phase Ib/II trial of combination PD-1 therapy against kidney cancer

8th - 12th Sep 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.09.17
Views: 686

Dr Chung-Han Lee - Memorial Sloan Kettering Cancer Center, New York, USA

Dr Lee speaks with ecancer at ESMO 2017 about the early results of combining lenvatinib, one of the current treatment options against metastatic renal carcinoma, with anti-PD1 pembrolizumab.

He outlines the endpoints for the trial including overall response (OR) at 24 weeks, and notes the improved response for treatment naïve patients compared to those who had been previously treated.

While median PFS has not yet been met, Dr Lee is optimistic that the responses so far will translate to survival, and introduces phase III trials including lenvatinib and pembrolizumab as an investigative arm.

Fore more on this study, read our news coverage here.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence